A Double-Blind, Randomized, Single-Dose Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

Trial Profile

A Double-Blind, Randomized, Single-Dose Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Triamcinolone (Primary) ; Triamcinolone
  • Indications Osteoarthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors Flexion Therapeutics
  • Most Recent Events

    • 06 Oct 2017 According to a Flexion Therapeutics media release, the U.S. Food and Drug Administration (FDA) approved Zilretta (triamcinolone acetonide extended-release injectable suspension), the first and only extended-release, intra-articular injection for osteoarthritis knee pain.
    • 07 Sep 2017 According to a Flexion Therapeutics media release, post-hoc pooled analysis of this and two other trials (see CT profiles 210815 and 243924) will be presented at PAINWeek 2017.
    • 10 Jul 2017 According to a Flexion Therapeutics media release, data from this trial will be highlighted in an Investor & Analyst Day 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top